Literature DB >> 22386738

The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses.

Shingo Kato1, Eriko Hosomi, Fumi Amano, Taisuke Kobayashi, Kazuhito Kani, Ryuichi Yamamoto, Tomonari Ogawa, Akihiko Matsuda, Yoshiki Sato, Seiichi Izaki, Tetsuya Mitarai, Koji Yakabi.   

Abstract

BACKGROUND AND AIMS: Subcutaneous aseptic abscess is one phenotype of neutrophilic dermatitis. We were interested to see if a case of steroid refractory Crohn's disease (CD) complicated by subcutaneous aseptic neutrophilic abscesses responds to intensive granulocyte/monocyte adsorptive apheresis (GMA).
METHODS: The patient was a 21-year-old male with worsening severe CD while on oral prednisolone (30 mg/day). His symptoms included fever, bloody diarrhoea and multiple painful subcutaneous nodules throughout his body. Skin biopsy showed chronic panniculitis with neutrophilic infiltrates. Further, colonoscopy showed oedematous sigmoid colon, while colonic biopsy showed non-caseous granuloma. Because biologics were feared to increase the risk of bacteraemia as the result of germ culture on his pus was not known at the time, we decided to treat this case with GMA. Five GMA sessions with the Adacolumn over 5 consecutive days (daily GMA) were initiated.
RESULTS: On admission, his CD activity index (CDAI) was 355, C-reactive protein (CRP) 11.2 mg/dL. After 5 GMA sessions, CDAI decreased to 170, and CRP fell to 5.0 mg/dL, with no fever. GMA was restarted at 2 sessions/week (total 10 sessions). The patient's CDAI fell to <150, and the skin lesions re-epithelialized.
CONCLUSIONS: In this CD case complicated by subcutaneous aseptic neutrophilic abscesses, GMA appeared to be effective. Our impression is that when biopsy reveals neutrophil infiltrate is a major feature of the lesions, GMA should be considered. As GMA appears to have no safety concerns, a frequent GMA protocol, like daily followed by 2 to 3 times/week should be preferred over the routine weekly GMA.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22386738     DOI: 10.1016/j.crohns.2012.02.005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  5 in total

Review 1.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 2.  Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future.

Authors:  Xiu-Li Chen; Jing-Wei Mao; Ying-De Wang
Journal:  World J Gastrointest Pathophysiol       Date:  2020-05-12

3.  Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA.

Authors:  Yoko Yokoyama; Mikio Kawai; Ken Fukunaga; Koji Kamikozuru; Kazuko Nagase; Koji Nogami; Tomoaki Kono; Yoshio Ohda; Masaki Iimuro; Nobuyuki Hida; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  BMC Gastroenterol       Date:  2013-02-12       Impact factor: 3.067

4.  Aseptic abscess syndrome associated with traveler's diarrhea after a trip to Malaysia.

Authors:  Zois Panos; George Giannopoulos; Eymorfia Papangeli; Emmanouil Antalis; Androula Pavli; Aris Spathis; Garyfalia Poulakou; George Dimitriadis; Ioannis Panayiotides; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  IDCases       Date:  2016-09-15

5.  Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis.

Authors:  Yoshiharu Yamaguchi; Marie Nakagawa; Shoko Nakagawa; Kazuhiro Nagao; Satoshi Inoue; Tomoya Sugiyama; Shinya Izawa; Yasutaka Hijikata; Masahide Ebi; Yasushi Funaki; Naotaka Ogasawara; Makoto Sasaki; Kunio Kasugai
Journal:  Intern Med       Date:  2020-09-30       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.